FKBP51 inhibits GSK3β and augments the effects of distinct psychotropic medications
Molecular Psychiatry2015Vol. 21(2), pp. 277–289
Citations Over TimeTop 13% of 2015 papers
Nils C. Gassen, Jakob Hartmann, Anthony S. Zannas, Anja Kretzschmar, Jürgen Zschocke, Giuseppina Maccarrone, Kathrin Hafner, Andreas Zellner, Lorenz Korbinian Kollmannsberger, Klaus V. Wagner, Divya Mehta, Stefan Kloiber, Christoph W. Turck, Susanne Lucae, George P. Chrousos, F Holsboer, Elisabeth B. Binder, Marcus Ising, Mathias V. Schmidt, Theo Rein
Related Papers
- → Use of lithium and SB‐415286 to explore the role of glycogen synthase kinase‐3 in the regulation of glucose transport and glycogen synthase(2003)62 cited
- → Synthesis of a Glycogen Synthase Kinase-3 Inhibitor(2010)2 cited
- [A new target for diabetes therapy: advances in the research of glycogen synthase kinase-3 inhibitors].(2007)
- Role of glycogen synthase kinase-3 in the pathogenesis of Alzheimer's disease(2011)